CRP and rheumatoid arthritis: The AVERT trial was a phase IIIb, multicenter, randomized, active controlled trial [45••] in which patients with <2 years of RA symptoms, DAS28 (CRP) ≥3.2, and anti-CCP2 positivity who were MTX naïve were randomized (1:1:1) to SC abatacept 125 mg/week plus MTX, abatacept monotherapy, or MTX alone for 12 months.